The methamphetamine experience: a NIDA partnership

Hanson, Glen R.; Rau, Kristi S.; Fleckenstein, Annette E.

doi:10.1016/j.neuropharm.2004.06.004

Cited by 70 publications

(54 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other drugs of abuse, such as cocaine and ( + )-methamphetamine have also been shown to produce seizure activity when administered to adult animals (Hanson et al, 1999) and in the case of ( + )-methamphetamine, neurotoxicity is induced (Hanson et al, 2004). While it might be suspected that rats exposed to doses of ( + )-methamphetamine that produce seizures and neurotoxicity would have nonspecific behavioral alterations, the contrary is more apparent.…”

Section: Effects Of 5-meo-diptmentioning

confidence: 99%

Alterations in Body Temperature, Corticosterone, and Behavior Following the Administration of 5-Methoxy-Diisopropyltryptamine (‘Foxy’) to Adult Rats: a New Drug of Abuse

Williams

Herring

Schaefer

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

Many drugs are used or abused in social contexts without understanding the ramifications of their use. In this study, we examined the effects of a newly popular drug, 5-methoxy-diisopropyltryptamine (5-MEO-DIPT; 'foxy' or 'foxy-methoxy'). Two experiments were performed. In the first, 5-MEO-DIPT (0, 10, or 20 mg/kg) was administered to rats four times on a single day and animals were examined 3 days later. The animals that received 5-MEO-DIPT demonstrated hypothermia during the period of drug administration and delayed mild hyperthermic rebound for at least 48 h. Corticosterone levels in plasma were elevated in a dose-dependent manner compared to saline-treated animals with minor changes in 5-HT turnover and no changes in monoamine levels. In experiment 2, rats were examined in behavioral tasks following either 0 or 20 mg/kg of 5-MEO-DIPT. The animals treated with 5-MEO-DIPT showed hypoactivity and an attenuated response to ( + )-methamphetamine-induced stimulation (1 mg/kg). In a test of path integration (Cincinnati water maze), 5-MEO-DIPT-treated animals displayed deficits in performance compared to the saline-treated animals. No differences were noted in the ability of the animals to perform in the Morris water maze or on tests of novel object or place recognition. The data demonstrate that 5-MEO-DIPT alters the ability of an animal to perform certain cognitive tasks, while leaving others intact and disrupts the endocrine system. 5-MEO-DIPT may have the potential to induce untoward effects in humans.

show abstract

Section: Effects Of 5-meo-diptmentioning

confidence: 99%

Alterations in Body Temperature, Corticosterone, and Behavior Following the Administration of 5-Methoxy-Diisopropyltryptamine (‘Foxy’) to Adult Rats: a New Drug of Abuse

Williams

Herring

Schaefer

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…These studies also show that METH causes toxicity of the striatal nerve terminals. Administration of amphetamines and its analogs like METH results in long-lasting neurochemical depletions in dopamine and serotonin levels, inhibition of tyrosine hydroxylase and tryptophan hydroxylase activity, and dopamine reuptake sites (Davidson et al, 2001;Hanson et al, 2004;McCann and Ricaurte, 2004). In addition to the damage at the dopamine terminals, there is emerging evidence demonstrating that METH causes injury to cell bodies in various brain regions.…”

Section: Introductionmentioning

confidence: 99%

Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice

2006

View full text Add to dashboard Cite

Methamphetamine (METH) is an illicit and potent psychostimulant, which acts as an indirect dopamine agonist. In the striatum, METH has been shown to cause long lasting neurotoxic damage to dopaminergic nerve terminals and recently, the degeneration and death of striatal cells. The present study was undertaken to identify the type of striatal neurons that undergo apoptosis after METH. Male mice received a single high dose of METH (30 mg/kg, i.p.) and were killed 24 h later. To demonstrate that METH induces apoptosis in neurons, we combined terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining with immunohistofluorescence for the neuronal marker neuron-specific nuclear protein (NeuN). Staining for TUNEL and NeuN was colocalized throughout the striatum. METH induces apoptosis in approximately 25% of striatal neurons. Cell counts of TUNEL-positive neurons in the dorsomedial, ventromedial, dorsolateral and ventrolateral quadrants of the striatum did not reveal anatomical preference. The type of striatal neuron undergoing cell death was determined by combining TUNEL with immunohistofluorescence for selective markers of striatal neurons: dopamine-and cAMP-regulated phosphoprotein, of apparent M r 32,000, parvalbumin, choline acetyltransferase and somatostatin (SST). METH induces apoptosis in approximately 21% of dopamine-and cAMP-regulated phosphoprotein, of apparent M r 32,000-positive neurons (projection neurons), 45% of GABA-parvalbumin-positive neurons in the dorsal striatum, and 29% of cholinergic neurons in the dorsal-medial striatum. In contrast, the SST-positive interneurons were refractory to METH-induced apoptosis. Finally, the amount of cell loss determined with Nissl staining correlated with the amount of TUNEL staining in the striatum of METH-treated animals. In conclusion, some of the striatal projection neurons and the GABAparvalbumin and cholinergic interneurons were removed by apoptosis in the aftermath of METH. This imbalance in the populations of striatal neurons may lead to functional abnormalities in the output and processing of neural information in this part of the brain. Keywords methamphetamine; apoptosis; striatum; projection neurons; interneurons Methamphetamine (METH) is a potent and addictive psychostimulant. The neurotoxic effects of this substituted amphetamine are associated with its ability to induce an overflow of dopamine in the synapse by displacing vesicular dopamine stores (Raiteri et al., 1979; Liang and Rutledge, 1982a,b;Schmidt et al., 1985;Sulzer et al., 1995). Displaced dopamine molecules and its metabolites can be readily oxidized to reactive quinones and semiquinones (Cadet and Brannock, 1998) and nitrogen radicals (Lipton and Rosenberg, 1994;Imam et al., 1999) that affect a wide range of modifications of proteins, sugars, and lipids. Augmented levels of dopamine in the synapse induced by METH have been shown in humans (Wilson et al., 1996;McCann et al., 1998), non-human primates (Seiden et al., 1976;Villemagne et al., 1998;Harvey e...

show abstract

“…Moreover, the ability of AMPH, as well as of METH, to increase DA synthesis in dopaminergic neurons further contributes to the elevation of cytosolic DA levels [25,319]. The accumulation of cytosolic DA and subsequent oxidation to quinones and reactive oxygen species may contribute significantly to the observed neurodegeneration following METH exposure [319,320]. Due to the effects of AMPH on DA uptake and vesicle filling, it is expected that AMPH exposure reduces the amount of DA released per vesicle.…”

Section: Amphetaminementioning

confidence: 99%

Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release

Westerink

2006

CNSNDDT

View full text Add to dashboard Cite

Dopaminergic neurotransmission is mediated by the vesicular release of dopamine (DA), i.e. DA exocytosis. DA exocytosis and its modulation are generally believed to affect neuronal communication, development, maintenance and survival, and contribute to extracellular DA levels in the brain. As a result, DA exocytosis likely plays an important role in several neurological and psychiatric disorders, like Parkinson's disease (PD) and schizophrenia. As exocytosis is part of a sophisticated ensemble of processes, it can be modulated at different levels, including DA synthesis, uptake and vesicular transport as well as Ca 2+ -homeostasis and exocytotic proteins. Nonetheless, to be effective, modulation of exocytosis should result in functional changes, which are reflected by changes in release frequency, vesicle contents, and the time course of the exocytotic event. As will be shown in this review, functional changes in DA exocytosis can be produced by e.g. pharmacological/drug treatment, feedback mechanisms and up/down-regulation of exocytosis-related proteins. Moreover, the mode of DA exocytosis, i.e. classical full fusion or kiss-and-run exocytosis, could also serve as a potential target for functional modulation of dopaminergic neurotransmission. Since the onset and progression of neurological and psychiatric disorders often show a strong correlation with changes in brain DA levels, DA synthesis, transport or uptake, the findings described in this review highlight the importance of the modulation of (the mode of) DA exocytosis for normal progression of dopaminergic neurotransmission and the potential of exocytotic processes as drug targets.

show abstract

The methamphetamine experience: a NIDA partnership

Cited by 70 publications

References 45 publications

Alterations in Body Temperature, Corticosterone, and Behavior Following the Administration of 5-Methoxy-Diisopropyltryptamine (‘Foxy’) to Adult Rats: a New Drug of Abuse

Alterations in Body Temperature, Corticosterone, and Behavior Following the Administration of 5-Methoxy-Diisopropyltryptamine (‘Foxy’) to Adult Rats: a New Drug of Abuse

Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice

Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release

Contact Info

Product

Resources

About